Evidence map›Paper›PMID 24301843›Full record

ReviewJournal of oncology practice2014

Review of electronic patient-reported outcomes systems used in cancer clinical care.

Roxanne E Jensen, Claire F Snyder, Amy P Abernethy, Ethan Basch, Arnold L Potosky, Aaron C Roberts, Deena R Loeffler, Bryce B Reeve

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of oncology practice, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06396702 (Emotion And Symptom-focused Engagement), which is not on this map. Cited by 160 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
160citing papers in PubMed, 8 pooled it
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06396702 nanot yet recruitingnot on this mapstarted 2024, after this paper: background citation

Emotion And Symptom-focused Engagement (EASE) Intervention for the Management of Emotional and Physical Symptoms Among Solid Organ Transplant Recipients-pilot Study

TypeinterventionalSponsorUniversity Health Network, TorontoRan2024 to 2027Enrolled120ConditionsTransplant, Failure,Kidney, Transplant, Failure, HeartArmsEASE-SOT
3 · Its place in the literature

Who cites it

160 citing papers in PubMed, 8 syntheses or guidelines pooled it, 307 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Patient and staff experiences with an EHR-Integrated Symptom Management Program (eSyM) in oncology.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Using patient-reported outcome measures to deliver enhanced supportive care to people with lung cancer: feasibility and acceptability of a nurse-led consultation model.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018
    Trial
  15. Feasibility and accessibility of electronic patient-reported outcome measures using a smartphone during routine chemotherapy: a pilot study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. Improving an electronic system for measuring PROs in routine oncology practice.Journal of cancer survivorship : research and practice · 2016
    Trial
  20. Evaluation of point-of-care PRO assessment in clinic settings: integration, parallel-forms reliability, and patient acceptability of electronic QOL measures during clinic visits.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2016
    Trial

100 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 3 countries.

Roxanne E JensenLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; The Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Duke Comprehensive Cancer Center, Duke University Medical Center, Durham; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; and Health Outcomes Group, Memorial Sloan-Kettering Cancer Center, New York, NY rj222@georgetown.edu.
Claire F SnyderLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; The Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Duke Comprehensive Cancer Center, Duke University Medical Center, Durham; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; and Health Outcomes Group, Memorial Sloan-Kettering Cancer Center, New York, NY.
Amy P AbernethyLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; The Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Duke Comprehensive Cancer Center, Duke University Medical Center, Durham; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; and Health Outcomes Group, Memorial Sloan-Kettering Cancer Center, New York, NY.
Ethan BaschLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; The Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Duke Comprehensive Cancer Center, Duke University Medical Center, Durham; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; and Health Outcomes Group, Memorial Sloan-Kettering Cancer Center, New York, NY.
Arnold L PotoskyLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; The Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Duke Comprehensive Cancer Center, Duke University Medical Center, Durham; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; and Health Outcomes Group, Memorial Sloan-Kettering Cancer Center, New York, NY.
Aaron C RobertsLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; The Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Duke Comprehensive Cancer Center, Duke University Medical Center, Durham; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; and Health Outcomes Group, Memorial Sloan-Kettering Cancer Center, New York, NY.
Deena R LoefflerLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; The Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Duke Comprehensive Cancer Center, Duke University Medical Center, Durham; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; and Health Outcomes Group, Memorial Sloan-Kettering Cancer Center, New York, NY.
Bryce B ReeveLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; The Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Duke Comprehensive Cancer Center, Duke University Medical Center, Durham; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; and Health Outcomes Group, Memorial Sloan-Kettering Cancer Center, New York, NY.
Memorial Sloan Kettering Cancer Center · USAmgen (Switzerland) · CHDendreon (United States) · USDuke Medical Center · USGeorgetown University Medical Center · USPfizer (United Kingdom) · GBSidney Kimmel Comprehensive Cancer Center · US

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI STEPHEN W BYERS · 1990 to 2026
$71.5M
NCI NIH HHS P30 CA051008NCI NIH HHS P30CA051008
6 · The paper itself

Abstract

purposeThe use of electronic patient-reported outcomes (PRO) systems is increasing in cancer clinical care settings. This review comprehensively identifies existing PRO systems and explores how systems differ in the administration of PRO assessments, the integration of information into the clinic workflow and electronic health record (EHR) systems, and the reporting of PRO information.

methodsElectronic PRO (e-PRO) systems were identified through a semistructured review of published studies, gray literature, and expert identification. System developers were contacted to provide detailed e-PRO system characteristics and clinical implementation information using a structured review form.

resultsA total of 33 unique systems implemented in cancer clinical practice were identified. Of these, 81% provided detailed information about system characteristics. Two system classifications were established: treatment-centered systems designed for patient monitoring during active cancer treatment (n = 8) and patient-centered systems following patients across treatment and survivorship periods (n = 19). There was little consensus on administration, integration, or result reporting between these system types. Patient-centered systems were more likely to provide user-friendly features such as at-home assessments, integration into larger electronic system networks (eg, EHRs), and more robust score reporting options. Well-established systems were more likely to have features that increased assessment flexibility (eg, location, automated reminders) and better clinical integration.

conclusionThe number of e-PRO systems has increased. Systems can be programmed to have numerous features that facilitate integration of PRO assessment and routine monitoring into clinical care. Important barriers to system usability and widespread adoption include assessment flexibility, clinical integration, and high-quality data collection and reporting.

Indexed as

Electronic Health RecordsPatient Outcome AssessmentData CollectionHumansNeoplasms

Identifiers

PMID24301843
PMCPMC4094646
OpenAlexW2121051049

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.